17 completed, 4 active not recruiting, 4 withdrawn, 1 recruiting. 14 Phase 1, 11 Phase 2, 2 Phase 3, 1 Early Phase 1.
Follow IPI-145: new trials by email Literature Review of IPI-145 trials Research Report on IPI-145
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Follicular Helper T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 25 | 2026-08-03 | 2026-10-19 |
| Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Acalabrutinib, Duvelisib - Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 1 | Withdrawn | Narendranath Epperla | 2022-07-01 | 2022-06-07 | |
| Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study Duvelisib, Tisagenlecleucel - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Completed | Emory University | 4 | 2022-01-13 | 2025-01-20 |
| Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome Biospecimen Collection, Computed Tomography, Duvelisib - Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 38 | 2021-10-21 | 2026-07-31 |
| Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Duvelisib - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 15 | 2020-05-13 | 2026-01-05 |
| Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma Duvelisib, Nivolumab - Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | David Bond, MD | 7 | 2019-11-05 | 2024-05-02 |
| A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma Duvelisib - Indolent Non-Hodgkin Lymphoma | Phase 2 | Completed | SecuraBio | 103 | 2019-09-24 | 2024-09-19 |
| Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Duvelisib, Venetoclax - Chronic Lymphocytic Leukemia, Richter Syndrome | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 55 | 2018-07-12 | 2026-03-23 |
| A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Duvelisib - Peripheral T-cell Lymphoma | Phase 2 | Completed | SecuraBio | 156 | 2018-02-22 | 2025-03-07 |
| Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas Romidepsin, Bortezomib, duvelisib - Lymphoma, Relapsed/Refractory T-cell Lymphomas | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 114 | 2016-05-23 | 2026-04-24 |
| A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145) Duvelisib - Hematologic Malignancy | Phase 2 | Completed | SecuraBio | 19 | 2016-04-01 | 2023-09-11 |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) Duvelisib, Placebo, Rituximab - Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma | Phase 3 | Withdrawn | SecuraBio | 2015-12-01 | 2021-03-17 | |
| Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) Duvelisib, Rituximab, R-CHOP - Lymphoma | Phase 2 | Withdrawn | SecuraBio | 2015-12-01 | 2021-03-17 | |
| Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma duvelisib - Lymphoma | Phase 1 | Completed | AbbVie | 7 | 2015-11-01 | 2017-02-06 |
| Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145 IPI-145 (duvelisib), IPI-145 - Healthy | Phase 1 | Completed | SecuraBio | 103 | 2014-11-01 | 2021-03-17 |
| A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL IPI-145, Fludarabine, Cyclophosphamide - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 32 | 2014-06-27 | 2026-10-22 |
| Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects IPI-145 - Hepatic Impairment | Phase 1 | Completed | SecuraBio | 24 | 2014-03-01 | 2021-03-17 |
| IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) IPI-145, Follow-up Visit/Call - Leukemia | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2013-12-01 | 2014-01-06 | |
| A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 IPI-145, Ofatumumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Completed | SecuraBio | 99 | 2013-12-01 | 2023-09-21 |
| Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145 IPI-145, Rifampin - Healthy | Phase 1 | Completed | SecuraBio | 14 | 2013-10-01 | 2021-03-17 |
Showing 20 of 26. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma (5) · Lymphoma, T-Cell (4) · Hematologic Neoplasms (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Recurrence (2) · Arthritis, Rheumatoid (1) · Burkitt Lymphoma (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Leukemia (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Peripheral (1) · Mycosis Fungoides (1)
SecuraBio (14) · City of Hope Medical Center (2) · Dana-Farber Cancer Institute (2) · AbbVie (1) · David Bond, MD (1) · Emory University (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Narendranath Epperla (1) · National Cancer Institute (NCI) (1) · SCRI Development Innovations, LLC (1)
United States (20) · Italy (5) · Germany (4) · United Kingdom (4) · Hungary (3) · Belgium (2) · Bulgaria (2) · Czechia (2) · France (2) · Japan (2) · Netherlands (2) · New Zealand (2) · Poland (2) · Russia (2) · Spain (2)
Hagop Youssoufian, MD (10) · Alexey V Danilov (1) · Christina Poh (1) · David Bond, MD (1) · Edmund K Waller, MD, PhD (1) · Ian Flinn, M.D. (1) · Matthew Davids, MD (1) · Matthew S Davids, MD (1) · Narendranath Epperla, MD (1) · Neha Mehta-Shah (1) · Steven Horwitz, MD (1) · Susan O'Brien, MD, BA (1)
PMID 30742566, PMID 33786583, PMID 38836342, PMID 38886623, PMID 41886642, PMID 42018969
2019 (2), P30CA033572 (2), 2015 (1), P30CA138292 (1), UM1CA186689 (1)